Trial Profile
A phase II study of Nivolumab re-challenge therapy after VEGF inhibitor therapy in patients with advanced non-small cell lung cancer. Gunma-Ibaraki-Fukushima-Tochigi (GIFT) group study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms GIFT
- 25 Jan 2018 New trial record